Dr. Paul Calise MD - Kingsberg Medical

Paul Calise MD

Neurologist

Dr. Calise is a recognized expert in cognitive decline, neurological disorders, and Psycho Pharmacology and he has lectured extensively on these subjects. He is a compassionate physician who treats all of his patients as individuals. He is dedicated to a holistic approach to medicine resulting in the best possible patient care.

Education

College

College of Staten Island
Staten Island, New York
B.S. 1974

Medical School

Autonomous university of Guadalajara
Guadalajara, Mexico
M.D. 1979

5th Pathway

New York Medical College
St. Joseph’s Hospital
Staten Island, New York

Residencies

Internal Medicine

St. Vincent’s Medical Center
Staten Island, New York
1982 – 1983

Neurology

Downtown Medical Center
Brooklyn, New York
1983-1986
Chief Resident
July 1985 – July1986

Work History

Medical Neurology

625 South East 3rd Avenue, # 400
Ft. Lauderdale, FL 33316
1986 – 1994

North Ridge Neuroscience Center

Calise,Steingo,Kishner, M.D., PA
Director : Memory Institute
5757 N. Dixie Highway
Ft. Lauderdale, FL 33334
1994 – 1999

Sunrise Medical

Neurology Private Practice
572 – McNab St.
Pompano Beach , Fl 33339
2000 – 2009

Neurology of South Florida

2021 E Commercial Blvd.
Fort Lauderdale, Fl. 33308
2009 – 2018

Licenses

State of Florida

#ME 48776
1986

State of New York

#145708
1986

Societies

American Medical Association

America College of Physicians

Academy of Neurology

Board Certifications

Diplomat, American Board of Internal
Medicine
1984

Board Eligibility

The American Board of Neurology
July 1986

Awards

Bodine Physician Award for top
Medical Resident
1983

Speaker for Pharmaceutical Companies

Regional speaker for Forest Pharmaceuticals

Advances in Alzheimer’s with Namenda

Regional speaker for Pfizer Pharmaceuticals

Pain management with Lyrica

Migraine treatment with Relpax

Regional speaker for GSK/GlaxoSmithKline

Migraine treatment with Imitrex, Treximet

Regional speaker for Boehringer Ingelheim

Stroke and TIA management with Aggrenox

Lectures

Neurologic Lecture of North Broward Hospital Dist.
Nursing Association
1988

Comprehensive Management of AIDS patients:
Treatment Team Workshop, Dania FL
1988

Alzheimer’s Association: A Regional
Alzheimer’s Disease Conference;
February 25, 1999

Psycho Pharmacology: Updates on current medications
For dementia and related psychiatric disorders and Behavioral problems.

Research

Neurological Associates
572 East McNab Road, Suite 202
Pompano Beach, FL 33060
1999 – present

Experience

TEVA Neuroscience, Protocol TNC GA
Indication - Multiple Sclerosis
2006

Biogen, IDEC & Elan Pharmaceuticals, Protocol 101-MS-322
Indication - Multiple Sclerosis
2006

Takeda Global Research, Protocol 01-05-TL-375-061
Indication - Alzheimer’s disease
2006

Novartis Pharmaceuticals Corp., Protocol Stalevo/CEL200A
Indication - Parkinson’s disease with end-of-dose wearing off
2005 – 2006

Protein Design Labs, Inc., Protocol DAC-1012
Indication- Multiple Sclerosis
2005 – 2006

Myriad Pharmaceuticals, Protocol MPC-7869
Indication- Alzheimer’s disease
2005 – 2006

Acadia Pharmaceuticals, Protocol ACP 103-010
Indication- Parkinson’s disease with psychosis
2005 – 2006

Eisai Medical Research, Protocol TVP-1012-A001-201
Indication- Alzheimer’s disease with Mild to Moderate Dementia
2005 – 2006

Merck Germany, Protocol EMR 62 225 030
Indication- Parkinson’s disease with dyskinesia
2005 – 2006

Merck Germany, Protocol EMR 62 225 019
Indication- Parkinson’s disease with dyskinesia
2004 – 2006

Acadia Pharmaceuticals, Protocol SCP 103-006
Indication- Parkinson’s disease with psychosis
2004 – 2006

Biogen Idec, Protocol C-1808
Indication- Multiple Sclerosis
2004 – 2006

INC Research, Protocol 02-AVR-107
Indication- Pseudobulbar Affect
2002 – 2006

ILEX Pharmaceuticals, Inc., Protocol CAMMS 223
Indication- Multiple Sclerosis
2002 – 2006

Schwarz BioSciences, Protocol SP512
Indication- Parkinson’s Disease
2001 – 2006

Schwarz BioSciences, Protocol SP650
Indication- Parkinson’s Disease
2001 – 2006

Biogen Idec, Protocol C-1802
Indication- Multiple Sclerosis
2001 – 2005

Mylan Pharmaceuticals Inc. Protocol APO401
Indication- Parkinson’s Disease
2000 – 2005

INC Research, Protocol 02-AVR-106
Indication- Pseudobulbar Affect
2002 – 2004

Sention, Inc., Protocol 22018
Indication- Anterior Communicating Artery Aneurysm
2002 – 2003

Serono, Inc., Protocol 22982
Indication- Multiple Sclerosis
2001 – 2002

Janssen Pharmaceuticals Inc., Protocol GAL-USA 23,
Indication- Alzheimer’s Disease
2001 – 2002

Biogen, inc., Protocol C-858
Indication- Multiple Sclerosis
2001

Novartis Pharmaceuticals Inc., Protocol CCOM998 US01
Indication- Parkinson’s Disease
2000 – 2001